A study to find out if a vaccine designed to protect against a disease (group B meningococcal meningitis) is safe and protects toddlers aged 12 <18months or 18 < 24 months

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004400-38

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

•To describe the immune response as measured by hSBA performed with 4 primary MnB strains, 2 expressing an LP2086 subfamily A protein and 2 expressing an LP2086 subfamily B protein, measured 1 month after the third vaccination with bivalent rLP2086 vaccine, in healthy toddlers aged 12 to <18 months at study entry. •To describe the immune response as measured by hSBA performed with 4 primary MnB strains, 2 expressing an LP2086 subfamily A protein and 2 expressing an LP2086 subfamily B protein, measured 1 month after the third vaccination with bivalent rLP2086 vaccine, in healthy toddlers aged 18 to <24 months at study entry.


Critère d'inclusion

  • Invasive meningococcal disease (IMD) caused by Neisseria meningitidis
  • serogroup B

Liens